Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the iQ-Check Vibrio Real-Time PCR Detection Kit, a fast and accurate method to detect the three main Vibrio species that cause vibriosis, a disease linked to approximately 80,000 illnesses in the U.S. every year.
HERCULES, Calif — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the iQ-Check Vibrio Real-Time PCR Detection Kit, a fast and accurate method to detect the three main Vibrio species that cause vibriosis, a disease linked to approximately 80,000 illnesses in the U.S. every year.
The presence of three Vibrio species in particular: V. cholerae, V. parahaemolyticus, and V. vulnificus, in raw or undercooked seafood, represents a serious threat to human health as they can cause human illness in the intestinal tract. Unfortunately, the standard reference method used to determine the presence of Vibrio is labor-intensive. Further, it can take up to seven days to get test results. While real-time PCR methods offer quicker turnaround times, these methods can be prone to false positives due to free DNA found in the sample.
The iQ-Check Vibrio Real-Time PCR detection Kit provides seafood companies and laboratories that test for food pathogens with a faster, more accurate alternative. The process uses the Vibrio Enrichment Broth that promotes the growth of Vibrio while inhibiting associated competitive flora. The broth shortens culture times from 18 to eight hours, and the entire detection process can be completed within 11 hours.
The iQ-Check Vibrio Kit reduces false positives by using Bio-Rad’s Free DNA Removal Solution that eliminates free DNA from the sample and provides specialized probes and primers that help prevent nonspecific DNA amplification. A synthetic DNA internal control is included in the iQ-Check Vibrio Kit reaction mix to validate any possible negative results.
The kit is also well suited for laboratories with high throughput demands. As part of their workflow, they may use Bio-Rad’s iQ-Check Prep Automation System, which automates DNA extraction and PCR plate setup and can process more than 500 samples in an eight-hour shift.
Please visit www.bio-rad.com/vibrio to learn more.
Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions and iQ-Check is a trademark of Bio-Rad Europe GmbH in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “can,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Press Contact:
Bio-Rad Laboratories, Inc.
Wendy Lauer
510-741-5653
wendy_lauer@bio-rad.com
